Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non–small cell lung cancer
- 1 August 2005
- Vol. 138 (2) , 360-367
- https://doi.org/10.1016/j.surg.2005.06.016
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Phase I study of oral suberoylanilide hydroxamic acid (SAHA), a histone deacetylase inhibitor, in patients (pts) with advanced leukemias or myelodysplastic syndromes (MDS)Journal of Clinical Oncology, 2004
- A Review of Depsipeptide and Other Histone Deacetylase Inhibitors in Clinical TrialsCurrent Pharmaceutical Design, 2004
- Histone deacetylase (HDAC) inhibitor activation of p21 WAF1 involves changes in promoter-associated proteins, including HDAC1Proceedings of the National Academy of Sciences, 2004
- Identification and Characterization of a Novel p300-mediated p53 Acetylation Site, Lysine 305Journal of Biological Chemistry, 2003
- Ineffectiveness of Histone Deacetylase Inhibitors to Induce Apoptosis Involves the Transcriptional Activation of NF-κB through the Akt PathwayJournal of Biological Chemistry, 2003
- Histone deacetylase inhibitors in cancer treatmentAnti-Cancer Drugs, 2002
- Histone deacetylase inhibitors as new cancer drugsCurrent Opinion in Oncology, 2001
- Emerging roles for chromatin remodeling in cancer biologyTrends in Cell Biology, 2001
- Duration of Nuclear NF-κB Action Regulated by Reversible AcetylationScience, 2001
- Roles of histone acetyltransferases and deacetylases in gene regulationBioEssays, 1998